Back to Search Start Over

Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine.

Authors :
Samusieva, Anastasiia
Serga, Svitlana
Klymenko, Sergiy
Rybchenko, Lyudmila
Klimuk, Bohdana
Zakhartseva, Liubov
Gorovenko, Natalia
Lobanova, Olga
Rossokha, Zoia
Fishchuk, Liliia
Levkovich, Nataliia
Medvedieva, Nataliia
Popova, Olena
Cheshuk, Valeriy
Inomistova, Mariia
Khranovska, Natalia
Skachkova, Oksana
Michailovich, Yurii
Ponomarova, Olga
Kozeretska, Iryna
Source :
Breast Cancer Research & Treatment; Oct2022, Vol. 195 Issue 3, p453-459, 7p
Publication Year :
2022

Abstract

Purpose: The gene BRCA1 plays a key role in DNA repair in breast and ovarian cell lines and this is considered one of target tumor suppressor genes in same line of cancers. The 5382insC mutation is among the most frequently detected in patients (Eastern Europe) with triple-negative breast cancer (TNBC). In Ukraine, there is not enough awareness of necessity to test patients with TNBC for BRCA1 mutations. That is why this group of patients is not well-studied, even through is known the mutation may affect the course of disease. Methods: The biological samples of 408 female patients were analyzed of the 5382insC mutation in BRCA1. We compared the frequency of the 5382insC mutation in BRCA1 gene observed in Ukraine with known frequencies in other countries. Results: For patients with TNBC, BRCA1 mutations frequency was 11.3%, while in patients with luminal types of breast cancers, the frequency was 2.8%. Prevalence of 5382insC among TNBC patients reported in this study was not different from those in Tunisia, Poland, Russia, and Bulgaria, but was higher than in Australia and Germany. Conclusion: The BRCA1 c.5382 mutation rate was recorded for the first time for TNBC patients in a Ukrainian population. The results presented in this study underscore the importance of this genetic testing of mutations in patients with TNBC. Our study supports BRCA1/2 genetic testing for all women diagnosed with TNBC, regardless of the age of onset or family history of cancer and not only for women diagnosed with TNBC at <60y.o., as guidelines recommend. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01676806
Volume :
195
Issue :
3
Database :
Complementary Index
Journal :
Breast Cancer Research & Treatment
Publication Type :
Academic Journal
Accession number :
159032478
Full Text :
https://doi.org/10.1007/s10549-022-06692-3